<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36924861</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7573</ISSN><JournalIssue CitedMedium="Internet"><Volume>310</Volume><PubDate><Year>2023</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of ethnopharmacology</Title><ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation></Journal><ArticleTitle>Kunxian capsule alleviates renal damage by inhibiting the JAK1/STAT1 pathway in lupus nephritis.</ArticleTitle><Pagination><StartPage>116349</StartPage><MedlinePgn>116349</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2023.116349</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-8741(23)00217-9</ELocationID><Abstract><AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Kunxian capsule (KXC) is a new traditional Chinese medicine drug included in "The key science and technology achievements" in the Ninth Five Year Plan of China. KXC has been clinically used for more than 10 years in the treatment of lupus nephritis (LN). However, the underlying role and molecular mechanism of KXC in LN remain unclear.</AbstractText><AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">This study aimed to explore the efficacy and potential mechanisms of KXC through pharmacological network, in vitro and in vivo studies.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Pharmacological network analysis of KXC treatment in LN was performed using data acquired from the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP, https://old.tcmsp-e.com/tcmsp.php) and NCBI Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/database). HK-2&#xa0;cells were chosen as an in vitro model of the tubular immune response by simulation with interferon &#x3b3; (IFN-&#x3b3;). MRL/lpr mice were used to explore the mechanism of KXC in vivo. Finally, the specific active molecules of KXC were further analyzed by molecular docking.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The pharmacological network analysis showed that STAT1 is a key factor in the effects of KXC. In vitro and in vivo experiments confirmed the therapeutic effect of KXC on LN renal function and tubular inflammation. The protective effect of KXC is mediated by STAT1 blockade, which further reduces T-cell infiltration and improves the renal microenvironment in LN. Two main components of KXC, Tripterygium hypoglaucum (H.L&#xe9;v.) Hutch (Shanhaitang) and Epimedium brevicornu Maxim (Yinyanghuo) could block JAK1-STAT1 activation. Furthermore, we found 8 molecules that could bind to the ATP pocket of JAK1 with high affinities by performing docking analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">KXC inhibits renal damage and T-cell infiltration in LN by blocking the JAK1-STAT1 pathway.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Rongrong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingjian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, Guangzhou, 510642, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center of Clinical Laboratory, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Qunqun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Baiyunshan Chenliji Pharmaceutical Co., Ltd, Guangzhou, 510288, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaolan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Baiyunshan Chenliji Pharmaceutical Co., Ltd, Guangzhou, 510288, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Minmin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of Clinical Laboratory, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Gaopeng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, Guangzhou, 510642, China. Electronic address: songgp1021@scau.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Renan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Baiyunshan Chenliji Pharmaceutical Co., Ltd, Guangzhou, 510288, China. Electronic address: qinrenan@813zy.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shuwen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China; State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, 510515, China. Electronic address: liusw@smu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>J Ethnopharmacol</MedlineTA><NlmUniqueID>7903310</NlmUniqueID><ISSNLinking>0378-8741</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000625858">kunxian</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494080">Stat1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050794">STAT1 Transcription Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050794" MajorTopicYN="N">STAT1 Transcription Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">JAK1</Keyword><Keyword MajorTopicYN="N">Kunxian capsule</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Renal microenvironment</Keyword><Keyword MajorTopicYN="N">STAT1</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Baiyunshan Chenliji Pharmaceutical Co., Ltd provided the bulk drug and partly financial support of this study. We have fully disclosed the interests to Journal of Ethnopharmacology and developed an approval plan to manage any potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>20</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36924861</ArticleId><ArticleId IdType="doi">10.1016/j.jep.2023.116349</ArticleId><ArticleId IdType="pii">S0378-8741(23)00217-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>